透過您的圖書館登入
IP:18.189.2.122
  • 期刊

胸腔病例(三九三)特發性肺纖維化合併肺癌

摘要


根據大型研究的統計結果,特發性肺纖維化的患者罹患肺部惡性腫瘤的發生率是一般族群的5倍之多,即使排除吸菸史和高齡等危險因子帶來的影響,特發性肺纖維化患者仍有較高罹患肺癌的風險,由於疾病本身帶來的肺部發炎和纖維化,以及患者常須接受免疫調節藥物(immunomodulatory medications)控制病情的特性,特發性肺纖維化疾病本身已被認為是罹患肺癌的獨立危險因子之一。

參考文獻


Esposito DB, Lanes S, Donneyong M, et al. Idiopathic Pulmonary Fibrosis in United States Automated Claims. Incidence, Prevalence, and Algorithm Validation. Am J Respir Crit Care Med 2015;192:1200-7.
Cameli P, Refini RM, Bergantini L, et al. Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study. Front Mol Biosci 2020;7:581828.
Petnak T, Lertjitbanjong P, Thongprayoon C, et al. Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Chest 2021;160:1751.
Kato E, Takayanagi N, Takaku Y, et al. Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis. ERJ Open Res 2018;4:00111-2016.
Brown SW, Dobelle M, Padilla M, et al. Idiopathic Pulmonary Fibrosis and Lung Cancer. A Systematic Review and Meta-analysis. Ann Am Thorac Soc 2019;16:1041.

延伸閱讀